Discover our european  projects

Synergizing on a multistakeholder level to accelerate clinical translation and therapy availability

Discover our european projects

Synergizing on a multistakeholder level to accelerate clinical translation and therapy availability

European initiatives

The Chair for Cellular Immunotherapy is part of these European consortia funded by the EU

EU Project imSAVAR

Nonclinical mimicking of the immune system effects of immunomodulatory therapies. The imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of immunomodulatory therapies.

We also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them. Please find out more about the initial challenge, our approach, and objectives, as well as the intended impact below.

EU Project T2EVOLVE

The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered
T-cell receptor (TCR) or synthetic chimeric antigen receptor CaAR.

Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

EU Project AIDPATH

AIDPATH aims to facilitate patients access to CAR T cell therapy by creating a fully automated CAR T cell manufacturing pipeline that can be placed in the hospital itself.

SmartCAR-T

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease. Eleven partners in six European countries have closely collaborated to transfer the CAR-T “Breakthrough Therapy” from bench to bedside.

We anticipate that SmartCAR-T cells will confer more potent and durable antitumor reactivity. We will deliver a platform that can be rapidly adjusted to other tumor types. The TME-response functions are integrated into SmartCAR-T cells as a ‘stand alone, single shot treatment’ without the need for expensive combination therapy. This allows scalable economic production and broad patient access in a sustainable way for health care systems.

EU Project CARAMBA

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease. Eleven partners in six European countries have closely collaborated to transfer the CAR-T “Breakthrough Therapy” from bench to bedside.

CERTAINTY

CERTAINTY develops virtual twins to support CAR T cell therapy in cancer treatment. Virtual twins are data-driven digital models representing a patient’s health or disease state, designed to simulate and predict individual responses to therapy. The approach aims to provide clinicians with actionable insights to inform treatment decisions and improve personalized cancer care.

JOIN4ATMP

The JOIN4ATMP project aims to accelerate and de-risk European ATMP development and ensure wide-spread access of ATMPs, through the mapping of obstacles to such development, the audit of real-world-based solutions and the definition of new paths forward.

EASYGEN

EASYGEN is a collaborative EU project aiming to optimize hospital workflows of CAR-T cell therapy for a sustainable healthcare workforce. It brings together 18 international partners from academia and industry, and is led by Fresenius SE & Co.KGaA and Fraunhofer IZI as academic co-lead.

Clinical trials

We aim to accelerate the translation of innovative science to achieve new patient treatments

LION-1 Study
 

Principal investigator of the LION-1 trial is Prof. Hermann Einsele, Director of the Department of Medicine II at University Hospital Würzburg. Prof. Michael Hudecek is the sponsor representative of the study, Prof. Sophia Danhof leads the clinical treatment. The study is being conducted at the newly established Clinical Trial Center of the NCT WERA.

CARAMBA Study
 

The clinical trial within CARAMBA is designed as a Phase I/II trial. Phase I is a dose escalation study and will explore the effective dose of the CAR-T cell product. For the Phase II part of the trial, 25 patients will be treated with the maximum tolerated dose of SLAMF7 CAR-T.

European initiatives

The Hudecek Lab is currently part of four European consortia funded by the EU

EU Project imSAVAR

Nonclinical mimicking of the immune system effects of immunomodulatory therapies. The imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of immunomodulatory therapies.

We also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them. Please find out more about the initial challenge, our approach, and objectives, as well as the intended impact below.

EU Project T2EVOLVE

The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered
T-cell receptor (TCR) or synthetic chimeric antigen receptor CaAR.

Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

EU Project AIDPATH

AIDPATH aims to facilitate patients access to CAR T cell therapy by creating a fully automated CAR T cell manufacturing pipeline that can be placed in the hospital itself.

Clinical trials

We aim to accelerate the translation of innovative science to achieve new patient treatments

EU Project CARAMBA

CARAMBA is a phase I/IIa clinical study targeting SF7.

EU Project EURECART
 

EURE-CART project’s main object is to conduct a multicentre, first-in-man Phase I/IIa clinical trial to demonstrate the safety and the efficacy of CD44v6 CAR-T cell immunotherapy in acute myeloid leukaemia and multiple myeloma. 

Proof of concept initiative PoC

Proof of concept initiative PoC is a clinical phase I study targeting ROR1.